

Frontiers in Anti-Infective Drug Discovery



Editor:
M. Iqbal Choudhary



Bentham Books

Frontiers in Anti-Infective Drug Discovery

(Volume 10)

Edited By

M. Iqbal Chaudhary

*H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Karachi
Pakistan*

Frontiers in Anti-Infective Drug Discovery

(Volume 10)

Editor: M. Iqbal Chaudhary

ISSN (Online): 1879-663X

ISSN (Print): 2451-9162

ISBN (Online): 978-1-68108-934-8

ISBN (Print): 978-1-68108-935-5

ISBN (Paperback): 978-1-68108-936-2

© 2024, Bentham Books imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

First published in 2024.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	iii
CHAPTER 1 MANAGING POSTERIOR SEGMENT OCULAR INFECTIONS: A REVIEW OF PHARMACOTHERAPY	1
<i>Saurabh Verma, Abhidnya Surve, Shorya Vardhan Azad, Kumar Parmanand, Vinod Kumar, Rohan Chawla and Pradeep Venkatesh</i>	
INTRODUCTION	1
Endophthalmitis	1
<i>Sample Collection and Lab Testing</i>	2
Bacterial Endophthalmitis	3
<i>Antibiotics</i>	4
<i>Role of Corticosteroids</i>	6
<i>Role of Pars Plana Vitrectomy (PPV)</i>	7
Fungal Endophthalmitis	7
<i>Management of Subretinal Abscess</i>	10
Viral Infections	10
<i>HSV, VZV Retinitis</i>	11
<i>CMV Retinitis</i>	13
<i>Measles</i>	14
<i>Dengue</i>	15
<i>Chikungunya</i>	15
Parasitic Infections	15
<i>Toxoplasma</i>	15
CONCLUSION	17
REFERENCES	18
CHAPTER 2 DISCOVERY AND DEVELOPMENT OF ANTIMALARIAL DRUG-RESISTANCE REVERSAL AGENTS	24
<i>Phanankosi Moyo, Vinesh Maharaj, Sephora M. Mutombo, Warren Andrew Andayi, Linda Amoah, Kathithileni M. Kalili, Kwame Kumi Asare and Cynthia Amaning Danquah</i>	
INTRODUCTION	25
Malaria: A Health, Economic and Social Challenge	25
Malaria Control: The Perpetual Challenge of Drug-Resistance Emergence and Spread	26
Drug-Resistance Reversal Strategy: A Noble Approach to Complement Drug Discovery and Development Efforts	29
4-Aminoquinolines, A Class of Antimalarials Worth Preserving	31
DISCOVERY AND DEVELOPMENT OF RESISTANCE REVERSAL AGENTS FOR 4-AMINOQUINOLINES	31
Synthetic Compounds as Resistance Reversers of 4-Aminoquinolines	32
<i>Verapamil - A Classical 4-Aminoquinoline Drug-Resistance Reversal Agent</i>	32
<i>Reversed Chloroquine: Chloroquine-Reversal Agent Conjugates or Double Drugs</i> ...	34
<i>3-(Substituted-Phenylmethylene)-Pyrrolidines as Chloroquine-Resistance Reversal Agents</i>	37
<i>Adamantane and Pentacycloundecanilamine (PCU)-Chloroquine Conjugates as Reversed Chloroquines</i>	38
<i>Quinoline Dimers as Chloroquine-Resistance Reversal Agents</i>	39
<i>Dibenzylmethylamine-4-amino-7-chloroquinoline (Dibemethin) as Reversed Chloroquines</i>	40

<i>Dibenzosuberanylpiperazine Derivatives as Chloroquine-Resistance Reversal Agents</i>	42
<i>Carboxamide and Aminoquinoline–Carboxamide as Drug-Resistance Reversal Agents Targeting ABC13</i>	42
<i>Chlorpheniramine and its Analogues as Chloroquine-Resistance Reversal Agents</i>	43
<i>Xanthene Derivatives as Chloroquine-Resistance Reversal Agents</i>	44
<i>Nonylphenoethoxylates (NPEs) as Chloroquine-Resistance Reversal Agents</i>	46
<i>Combination of Prochlorperazine and Chloroquine as a Chloroquine-Resistance Reversal Strategy</i>	47
<i>Structure Activity Relationship Studies of Quinoline Drug-Resistance Reversal Agents</i>	47
Natural Products Derived Drug-Resistance Reversal Agents	48
<i>Natural Products from Artemisia annua as Chloroquine-Resistance Reversal Agents</i>	48
<i>Bisbenzylisoquinoline (BBIQ) Alkaloids from Plants as Chloroquine-Resistance Reversal Agents</i>	49
<i>Pavine-Benzyltetrahydroisoquinolines (pavine-BTIQ) Dimers from Hernandia Voyronii as Chloroquine-Resistance Reversal Agents</i>	51
<i>Compounds from the Strychnos Genus as Chloroquine-Resistance Reversal Agents</i>	53
<i>Indole Alkaloids as Chloroquine-Resistance Reversal Agents</i>	54
<i>Pregnanes as Natural Products with Chloroquine-Resistance Reversal Agents</i>	55
<i>Reversal Activities of Coumarins, Diterpenoids and Xanthones from Plants</i>	56
<i>Resistance Reversal Activities of Crude Plant Extracts</i>	57
FUTURE PERSPECTIVES AND CONCLUDING REMARKS	62
ACKNOWLEDGEMENTS	64
REFERENCES	65
CHAPTER 3 OMICS TECHNOLOGIES AND ANTI-INFECTIVE DRUG DISCOVERY	74
<i>Gloria G. Guerrero M., Juan Manuel Favela-H, Bryan A. Espinoza R., Isaias Balderas R. and Jose Olivares T.</i>	
INTRODUCTION	74
MECHANISM OF ACTION OF THE ANTI-INFECTIVE DRUGS	76
OMICS TECHNOLOGIES IN DRUG DISCOVERY	81
Genomics and Metagenomics	81
Metagenomics	82
Transcriptomics	85
Transcriptomic Technologies	86
Transcriptomics Applied to the Drug Discovery of Anti-infective Agents	88
Identification of New Strategies/targets for Anti-infective Drug Design	88
Classification of Mechanism of Action (MOA) Through Transcriptomics-based Workflows	90
Transcriptomic Workflows Aimed at Generating New Combinations of Existing Drugs	91
Proteomics and Metabolomics	91
Separation of Proteins by Charge and Molecular Weight	92
Detection of Post-translational Modification PTM	94
Analysis of Lysine- acetylated Proteins in <i>V. Vulnificus</i>	94
Isolation of Proteins Related to Multidrug Resistance	94
Metabolomics	95
Spectroscopic Techniques Applied to Determine the Chemical Profile of Bioactive Metabolites Produced by Bacteria and or Animals (Including Humans)	98
HIGHLIGHTS AND PERSPECTIVES/CONCLUSION	100
REFERENCES	100
CHAPTER 4 POSSIBLE CUTANEOUS ADVERSE EFFECTS OF ANTI-INFECTIVE VACCINATIONS	116
<i>Sevgi Akarsu and Fatma Polat</i>	

INTRODUCTION	116
Hepatitis B Virus Vaccine	121
Mumps, Measles, Rubella Vaccine	122
Diphtheria, Tetanus, Pertussis, and Polio Vaccines	123
Bacillus Calmette-Guérin Vaccine	124
Pneumococcal Conjugate Vaccine	126
Meningococcal Vaccines	127
Varicella Zoster / Herpes Zoster Vaccine	129
Influenza Vaccine	130
Human Papillomavirus Vaccine	131
COVID-19 Vaccine	132
DISCUSSION	135
CONCLUSION	138
REFERENCES	138
SUBJECT INDEX	150

PREFACE

The global COVID-19 pandemic has highlighted the importance of the prevention and treatment of infectious diseases. Today the world is faced with an increasing number of emerging and re-emerging infectious diseases and the imminent threat of the next global-scale pandemics. Neglected tropical diseases continue to affect a large number of people globally. Multi-drug resistance infections have made the treatment of even common infections a major challenge. In this context, continuous efforts to discover and develop safe and effective anti-infectious agents are imperative. Recent advances in genomics, molecular and structural biology, and enabling technologies, such as high throughput screening, have greatly improved our capacity to identify new molecular entities against prevalent, neglected, and rare infectious diseases. In this process, the identification of new drug targets plays a central role.

The 10th volume of *Frontiers in Anti-Infective Drug Discovery* reflects our continuous efforts to highlight the most recent and exciting developments in this crucially important field. The current volume is a collection of four comprehensive reviews, each focused on a specific aspect of anti-infective drug discovery and development.

Venkatesh *et al.* in their review focussed on the management and treatment of a common eye infection, called posterior segment ocular infection, caused by a range of microorganisms (bacterial, fungal, and viral). Authors have highlighted the challenges faced in the treatment of ocular infections, and recent advances in chemotherapeutic agents for the successful management of this debilitating disease.

Malaria, particularly drug-resistant malaria, is re-emerging as a major cause of global concern, resulting in increasing morbidity and mortality. Moyo *et al.* have contributed an article that highlights the major challenges in the development of anti-malarial drugs, and then focuses on a novel strategy for reversing the drug resistance in *Plasmodium falciparum* against old antimalarial agents, including artemisinin-based agents. Authors have discussed many of such drug resistance reversal agents, their current status of development, and the way forward.

Enabling technologies, particularly “omics” now play a key role in the field of anti-infectious drug discovery. Guerrero *et al.* have provided a comprehensive account of the unprecedented role of “omics” technologies, particularly genomics, metagenomics, transcriptomics, proteomics and metabolomics, in the rapid and cost-effective identification of anti-infectious drug leads, and their further development through pharmacological assessment and clinical trials.

Last but certainly not least, Akarsu and Polat have contributed a chapter on a very interesting aspect of the adverse effects on the skin as a result of vaccination. The authors have highlighted the reported cases of cutaneous adverse effects of various anti-infective vaccines based on an extensive literature review.

ii

The 10th volume of the *ebook* series is the result of efficient coordination and excellent management of the entire team of Bentham Science Publishers, and most importantly timely submissions from the authors. We greatly appreciate the efforts of Miss Asma Ahmed (Manager Publications) and the team leader Mr. Mahmood Alam (Director Publications) for putting together an excellent compilation of well-written articles. We sincerely hope readers will benefit from this excellent compilation of the most recent scientific work in the important field of anti-infectious drug discovery.

M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Karachi
Pakistan

List of Contributors

- Abhidnya Surve** Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
- Bryan A. Espinoza R.** Universidad Autonoma de Nuevo Leon, Facultad de Quimica, Monterrey, Nvo Leon, Mexico
- Cynthia Amaning Danquah** Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Ghana
- Fatma Polat** Dermatologist; Kızıllırmak District, Dumlupınar Boulevard, Next Level Residence, No: 3A/13, 06530, Çankaya, Ankara, Turkey
- Gloria G. Guerrero M.** Universidad Autonoma de Zacatecas, Unidad Academica de Ciencias Biologicas, Lab de Inmunobiologia, Campus II. Av Preparatoria S/N. Col. Agronomicas. Zacatecas, Zac, Mexico
- Isaias Balderas R.** Universidad Autonoma de la Ciudad de Mexico, Posgrado en Ciencias Genomicas, CDAD MX, Mexico
- Jose Olivares T.** Universidad Autonoma de la Ciudad de Mexico, Posgrado en Ciencias Genomicas, CDAD MX, Mexico
- Juan Manuel Favela-H** Universidad Juarez del Edo de Durango, Facultad de Ciencias Quimicas, Gomez Palacio, Dgo, Instituto Multidisciplinario de Ciencias AVICENA. Torreon, Coahuila. MEX, Mexico
- Kathithileni M. Kalili** Department of Physics, Chemistry & Material Science, University of Namibia, Private Bag 13301, 340 Mandume Ndemufayo Avenue, Pionierspark, Windhoek, Ghana
- Kumar Parmanand** Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
- Kwame Kumi Asare** Department of Biomedical Sciences, School of Allied Health Sciences, College of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana
- Linda Amoah** Immunology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
West African Center for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cellular and Molecular Biology, University of Ghana, Accra, Ghana
- Pradeep Venkatesh** Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
- Phanankosi Moyo** Department of Chemistry, Faculty of Natural and Agricultural Sciences, University of Pretoria, Pretoria 0028, South Africa
- Rohan Chawla** Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
- Sephora M. Mutombo** Department of Chemistry, Faculty of Natural and Agricultural Sciences, University of Pretoria, Pretoria 0028, South Africa
- Shorya Vardhan Azad** Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India

iv

- Saurabh Verma** Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
- Sevgi Akarsu** Dokuz Eylul University, Faculty of Medicine, Department of Dermatology, 35340 Inciralti, Izmir, Turkey
- Vinod Kumar** Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
- Vinesh Maharaj** Department of Chemistry, Faculty of Natural and Agricultural Sciences, University of Pretoria, Pretoria 0028, South Africa
- Warren Andrew Andayi** Department of Physical and Biological Sciences, Murang'a University of Technology Murang'a, Ghana

CHAPTER 1

Managing Posterior Segment Ocular Infections: A Review of Pharmacotherapy

Saurabh Verma¹, Abhidnya Surve¹, Shorya Vardhan Azad¹, Kumar Parmanand¹, Vinod Kumar¹, Rohan Chawla¹ and Pradeep Venkatesh^{1,*}

¹ Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India

Abstract: Ocular infections affecting the posterior segment of the eye can lead to severe visual disability. The infections can range from bacterial/fungal endophthalmitis to various types of viral retinitis to toxoplasma retinitis. In recent years there have been significant advances in the use of chemotherapeutic agents for managing these infections. In this review we discuss their management with anti-infective agents. The choice of drugs, alternatives, mode of delivery and duration of therapy are discussed.

Keywords: Acute retinal necrosis, Antibiotics, Antifungals, Antiviral, Chickengunya, CMV retinitis, Dengue, Endophthalmitis, Intravitreal, Measles, Ocular drug delivery, Toxoplasma chorioretinitis, Viral retinitis.

INTRODUCTION

Endophthalmitis

Endophthalmitis is the inflammation of inner ocular coats with exudation into the vitreous cavity, secondary to infection by a microorganism. Toxins produced by infectious agents along with host's immune response can cause rapid and irreversible damage to retinal tissue with the potential to cause blindness. Thus, endophthalmitis is a grave ophthalmic emergency.

Based on the mode of infection, endophthalmitis may be classified as exogenous or endogenous [1]. In exogenous endophthalmitis, there is an identifiable mechanism of intraocular seeding of an organism from an external route. Exogenous endophthalmitis is the most common type (>90%) and can further be classified as follows:

* **Corresponding author Pradeep Venkatesh:** Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; E-mail: venkyprao@yahoo.com

- 1- On the basis of mode of entry of infectious agent- post surgical, post intravitreal injection, post-traumatic, bleb-related endophthalmitis or associated with corneal ulcer.
- 2- On the basis of onset of symptoms and duration- acute onset, late onset, chronic.
- 3- On the basis of causative organism- bacterial, fungal, protozoal.

Endogenous endophthalmitis is an intraocular infection resulting from hematogenous spread from a primary focus of infection elsewhere in body and accounts for 2-8% of all cases of endophthalmitis [2, 3].

Acute post-operative endophthalmitis is the most common type of endophthalmitis, with cataract surgery, intravitreal injections and secondary intraocular lens implantation being the most common causes [4]. Normal flora of the eyelids and conjunctiva are frequent sources of contamination. Other potential sources, include contaminated instruments/ solutions, contaminated water, microbes in the air and resident on the surgeon and other personnel in the operation theater. Common causative organisms of endophthalmitis are summarized in Table 1 [1, 5 - 11].

Table 1. Common organisms causing endophthalmitis.

1.	Acute onset post-operative endophthalmitis- <i>Staphylococcus epidermidis</i> , <i>Staphylococcus aureus</i> , <i>Streptococcus viridans</i>
2.	Delayed onset post-operative endophthalmitis- <i>Propionibacterium</i> species, <i>Candida</i> species, <i>Staphylococcus epidermidis</i>
3.	Post traumatic endophthalmitis- <i>Staphylococcus aureus</i> , <i>Bacillus cereus</i>
4.	Post intravitreal injection endophthalmitis- <i>Staphylococcus epidermidis</i> , <i>Streptococcus viridans</i>
5.	Bleb associated endophthalmitis- <i>Streptococcus viridans</i> , <i>Haemophilus Influenzae</i> , <i>Staphylococcus species</i>
6.	With microbial keratitis- Gram negative organisms, <i>Staphylococcus aureus</i>
7.	Endogenous endophthalmitis- <i>Candida</i> species, <i>Aspergillus</i> species

Sample Collection and Lab Testing

Identification of causative organisms and their susceptibility to anti-microbial drugs is important in managing patients with endophthalmitis, particularly when there is poor response to injections given earlier on, based on empirical recommendations. Conjunctival swab and corneal biopsy can be sent for culture in presence of coexisting purulent discharge or corneal ulcer, respectively. Anterior chamber tap with a 27-gauge needle can also be useful but is of limited use because of poor rate of isolation [12].

Since vitreous is the primary site of organismal colonization in endophthalmitis, vitreous samples tend to yield the highest rate of positive culture or staining. Vitreous tap can be taken through a 23-gauge needle inserted through the pars plana route [13]. However, attempt to suck vitreous without cutting it first often results in a dry tap or inadequate sample. Also, inadvertent pull on the vitreous can also result in the formation of iatrogenic breaks and retinal detachment. Vitreous biopsy with a pars plana vitrectomy probe avoids the aforementioned complications and is considered a safer option. Usually, 0.2 ml to 0.3 ml of undiluted sample is considered adequate for various tests [14]. It is advisable that vitreous biopsy should be done without switching on infusion as it may result in dilution of the collected sample [15].

Gram and KOH staining can help in making an immediate distinction between fungal or bacterial endophthalmitis. For KOH preparation, a fresh sample is necessary. Both bacterial and fungal cultures should be sent at the earliest to recognized and experienced laboratories. In addition to culture, drug sensitivity tests should also be obtained. It is advisable to wait for 1 week and 2 weeks respectively for bacterial and fungal culture before declaring no growth [16]. Commonly used bacterial and fungal cultures are summarized in Table 2 [15 - 17].

Table 2. Commonly used bacterial and fungal culture media.

-	Media	Type of Organism Isolated
Bacterial cultures	Chocolate agar	Fastidious pathogens such as Neisseria and Haemophilus
-	Blood agar	Almost all bacteria
-	MacConkey agar	Gram negative enteric bacilli
-	Eosin methylene blue agar	Gram negative enteric bacilli
Fungal cultures	Sabouraud's Dextrose agar	All fungal organisms; especially useful for dermatophytes
-	Brain heart infusion agar	All fungal organisms

Bacterial Endophthalmitis

Intravitreal injection of the antibiotics is the preferred modality for drug delivery, as it achieves the required antibiotic concentration in the eye. Additional modes of antibiotic administration can be topical, intravenous and/or oral. A combination of the above modes is used according to clinical presentation and severity of symptoms.

Discovery and Development of Antimalarial Drug-Resistance Reversal Agents

Phanankosi Moyo^{1,*}, Vinesh Maharaj¹, Sephora M. Mutombo¹, Warren Andrew Andayi², Linda Amoah^{3,4}, Kathithileni M. Kalili⁵, Kwame Kumi Asare⁶ and Cynthia Amaning Danquah⁷

¹ Department of Chemistry, Faculty of Natural and Agricultural Sciences, University of Pretoria, Pretoria 0028, South Africa

² Department of Physical and Biological Sciences, Murang'a University of Technology Murang'a, Kenya

³ Immunology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana

⁴ West African Center for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cellular and Molecular Biology, University of Ghana, Accra, Ghana

⁵ Department of Physics, Chemistry & Material Science, University of Namibia, Private Bag 13301, 340 Mandume Ndemufayo Avenue, Pionierspark, Windhoek, Namibia

⁶ Department of Biomedical Sciences, School of Allied Health Sciences, College of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana

⁷ Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Ghana

Abstract: Despite the meritorious measures taken to curb the malaria scourge in the last two decades, the drug-resistance phenomenon threatens to reverse the gains made. Evidence of partial resistance against the first-line antimalarial drugs, the artemisinin-based combination therapies, in Africa, a region that accounts for 95% of global malaria cases, has aroused fears that it could spread fast and significantly jeopardise malaria control and eradication efforts. While the antimalarial drug discovery pipeline has several, encouraging candidates emerging through it, unfortunately, the attrition rate is high, with some candidates failing either in preclinical studies or clinical trials. Moreover, the rate of emergence of drug-resistant *Plasmodium* parasite strains far exceeds that of the drug discovery and development process. These challenges demand novel strategies to complement the discovery and development of new therapeutics. One such strategy is the reversal of *Plasmodium falciparum* resistance to old antimalarials by combining these drugs with agents that specifically target drug-resistance mechanisms. This strategy has been successfully used in the antibiotics field, with a classical successful example being the amoxicillin and clavulanic acid combina-

* Corresponding author Phanankosi Moyo: Department of Chemistry, Faculty of Natural and Agricultural Sciences, University of Pretoria, Pretoria 0028, South Africa; E-mails: phanankosimoyo@gmail.com; u13386842@tuks.co.za

tion. In this chapter, we present a case for the need to discover and develop antimalarial drug-resistance reversal agents to prolong the efficacy and use of currently available antimalarial quinoline drugs as well as the re-use of old antimalarial quinoline drugs that have been rendered ineffective by drug-resistance. Furthermore, we provide an overview of noteworthy significant innovations that have been made in the field in search for antimalaria drug-resistance reversal agents. We conclude by providing perspectives on how these efforts can be expedited.

Keywords: 4-aminoquinoline, Chloroquine, Drug-resistance, Malaria, *Plasmodium falciparum*, *P. falciparum* chloroquine resistance transporter (*PfCRT*), Mefloquine, *P. falciparum* multidrug-resistance-1 (*PfMDR1*) transporter, Quinine, Quinolines, Resistance breakers, Resistance reversal agents.

INTRODUCTION

Malaria: A Health, Economic and Social Challenge

Malaria, a tropical disease caused by an infection with unicellular parasitic protozoa of the genus *Plasmodium* transmitted by female *Anopheles* mosquitoes, has been a major health challenge to human beings since time immemorial, with documentation from as far back as 2700 BC making reference to the disease [1]. It is presently endemic in 85 countries with half the world's population at risk of getting infected [2]. Despite the concerted intervention measures, malaria remains a serious global public health burden. In 2020, it caused 241 million clinical cases resulting in 627 000 fatalities, with the World Health Organisation (WHO) Africa Region accounting for nearly 95% of those cases (Table 1) [2]. Children under the age of 5 years are amongst the most vulnerable, along with pregnant women, accounting for 77% of the deaths (Table 1) [2].

The impact of malaria extends beyond the compromise of the wellbeing of its victims to having a negative impact on the economy [3, 4]. There is concurrent poverty and economic burden on both individuals and the healthcare systems in malaria-endemic countries. For example, it has been reported that Africa is losing close to US\$12 billion of its Gross Domestic Product (GDP) per year while also causing stagnation in economic growth by as much as 1.3% [4]. Since 2001, countries in sub-Saharan Africa have been spending on average US\$300 million annually on malaria case management, a staggering amount to countries whose meager income resources are already overburdened and stretched by other pressing issues [3, 4]. In addition to the loss of household incomes, malaria also leads to work and school health-related absenteeism [3, 4], with the latter having been reported to range between 17 and 54% in some parts of Kenya [5].

Table 1. The health burden of malaria*.

WHO Region	Malaria Cases	Malaria Deaths	Health burden: Children and Pregnant Woman
Africa	228 000 000	602 000	<ul style="list-style-type: none"> ▪ 77% deaths were children <5 years ▪ In 33 African countries, 11 600 000 pregnancies were exposed to malaria resulting in 819 000 children with low birth weight
South-East Asia	5 000 000	9 000	
Eastern Mediterranean	5 700 000	12 300	
Western Pacific	1 700 000	3 200	
Americas	650 000	409	

*Source [2].

Malaria Control: The Perpetual Challenge of Drug-Resistance Emergence and Spread

Along with vector control, chemotherapeutic agents including the quinolines (Fig. 1) and artemisinin-based combination therapies (ACTs), have been decisive in the control of malaria [6]. Unfortunately, the use of antimalarial drugs has, historically and presently, been undermined by the emergence and spread of drug-resistant *Plasmodium* parasite strains (Table 2) [7, 8]. This has rendered drugs, such as Chloroquine, less effective, significantly curtailing their role and deployment in malaria control efforts.

Table 2. Antimalarial drug development and resistance emergence*.

Drug	Discovered	Launched	Resistance First Report	Resistance Associated Gene Mutations
Quinine	1820	19 th century	1910	<i>pfmdr1</i> , <i>pfmrp</i> , <i>pfhhe1</i>
Chloroquine	1936	1945	1957	<i>pfert</i> , <i>pfmdr1</i> , <i>pfmrp</i>
Proguanil	1945	1948	1949	<i>pfdhfr</i>
Amodiaquine	1940s	1940s	1954	<i>pfert</i>
S-P ^o	-	1967	1967	<i>pfdhps</i>
Artemisinin	1970s	1970s	2009	<i>kelch13</i>
Mefloquine	1970s	1970s	1982	<i>pfmdr1</i>
Halofantrine	1970s	1988	1992	<i>pfmdr1</i>
Atovaquone	1980s	1996	1996	<i>pfcytb</i>

*Source [9 - 14]. ^oS-P – sulphadoxine-pyrimethamine; *pfmdr1* – *P. falciparum* multidrug resistance 1; *pfmrp* – *P. falciparum* multidrug-resistance-associated protein; *pfhhe* – *P. falciparum* Na⁺/H⁺ exchanger; *pfert* – *P. falciparum* chloroquine-resistance transporter; *pfdhfr* – *P. falciparum* dihydrofolate reductase; *pfdhps* – *P. falciparum* dihydropteroate synthase; *pfcytb* – *P. falciparum* cytochrome b.

Omics Technologies and Anti-Infective Drug Discovery

Gloria G. Guerrero M.^{1,*}, Juan Manuel Favela-H², Bryan A. Espinoza R.³, Isaias Balderas R.⁴ and Jose Olivares T.⁴

¹ Universidad Autonoma de Zacatecas, Unidad Academica de Ciencias Biologicas, Lab de Inmunobiologia, Campus II. Av Preparatoria S/N. Col. Agronomicas. Zacatecas, Zac, Mexico

² Universidad Juarez del Edo de Durango, Facultad de Ciencias Quimicas, Gomez Palacio, Dgo, Instituto Multidisciplinario de Ciencias AVICENA. Torreon, Coahuila. MEX, Mexico

³ Universidad Autonoma de Nuevo Leon, Facultad de Quimica, Monterrey, Nvo Leon, Mexico

⁴ Universidad Autonoma de la Ciudad de Mexico, Posgrado en Ciencias Genomicas, CDAD MX, Mexico

Abstract: The design of novel, safe, and effective drugs of natural origin is a challenging issue. To screen and uncover the infinite world of antimicrobial agents derived from secondary metabolites for drug discovery requires the integration of high-throughput technologies such as biology systems (bioinformatics) and omics technologies. These technologies include genomics, metagenomics, transcriptomes, proteomics, and metabolomics). In the present chapter, we focused on revisiting several aspects of these technologies in order to emphasize their unprecedented contribution to drug discovery. In addition, they represent a step forward in pharmacological and clinical research.

Keywords: Anti-infective agents, Omic technologies, Drugs system biology, Secondary metabolites, Bioinformatics.

INTRODUCTION

The anti-infective agent compounds used against pathogenic and resistant bacteria can be either natural or synthetic. Herein, we focused on the naturally derived compound designed as a drug, targetable to any physiological process of the microbial organism. Marine ecosystems represent an enormous richness, a vast repertoire of natural products, to be characterized by eliminate their, chemical

* **Corresponding author Gloria G. Guerrero M.:** Universidad Autonoma de Zacatecas, Unidad Academica de Ciencias Biologicas, Lab de Inmunobiologia, Campus II. Av Preparatoria S/N. Col. Agronomicas. Zacatecas, Zac. Mexico; Tel: +52 4921564376; E-mails: gloriaguillermina@uaz.edu.mx and gloguerrero9@gmail.com

structure or by the mechanism of action; at this point, for example, the marine peptides from which several antimicrobial-like drugs are obtained (Fig. 1) [1 - 3].

Drug discovery is necessary to optimize the sourcing of scaled strain cultivation, scale production, and the poor growth of the producers that leads to low yield (low amount of the desired compound). However, advances in high- throughput technologies have allowed us to trace a path to approach microbial-community genomes for elucidating biosynthetic gene clusters and natural drug-encoded products.

Next-generation therapeutics shaped by high-performance sequencing methodologies (NGS) allow the exploration and discovery of novel and improved anti-infective drugs. Genomic studies produce large databases of molecular information on potential druggable and targetable proteins, similarly accumulating data on proteomics, metagenomics, and transcriptomics. Next-generation therapeutics shaped by high-performance sequencing methodologies permit the exploration and discovery of novel and improved anti-infective drugs. Genomic studies produce large databases of molecular information on potential druggable and targetable proteins and, in a similar fashion accumulate data on proteomics, metagenomics, and transcriptomics. Furthermore, NGS provides insight into the pattern of gene expression and the pattern of drug discovery. It is essential to harness the power of omics technologies of NGS, and robotic high-throughput screening of the diverse and vast pool of natural compounds and secondary metabolites, in combination with *in-silico* and fragment-based screening techniques, new structural biology methods for rational drug desing, especially high-throughput tools in Metabolomics such as the Matrix-Assisted Laser Desorption/Ionization-Time-Of-Flight (MALDI-TOFF); Nuclear Magnetic Resonance (RMN), Liquid Gas Chromatography (LGC), and other advanced chemical technologies, including combinatorial and parallel synthesis. The pharmacokinetic and metabolic properties of the anti-infective drugs elucidate the development of validated pharmacodynamics end-points and molecular markers of drug response, ideally using non-invasive imaging technologies. Gene-expression microarray technologies are very useful for defining detailed molecular signatures of drug action. This technology can identify on-target and off-target effects and can determine and analyze molecular biomarkers for proof-of-concept studies, pharmacological end points and, to date, the development of new therapeutic agents. Furthermore, structured genomic information employed to identify classes of compounds for which detailed experimental structure-activity studies have been conducted, *e.g.*, the identification of Quinones whose pattern of activity correlated strongly with the expression patterns of particular genes. Moreover, microarray technologies have been useful. Other examples in drug discovery involve inhibitors of transcription factors (under conditions of

inflammation and hypoxia, the expression of mPEGS1, regulated by transcription factors) [4], and/or other chronic diseases, including Alzheimer's and Huntington's disease [5 - 8]. Proteomic and metabolomics technologies have made it possible to understand how epigenetics (culture conditions, interspecies cross-talk, stressors, environmental, nutritional factors, genotypes, cell type, and tissues) can modulate metabolic and signaling proteins in the different biologic processes. This approach also depends on the identification of protein-like targets (metabolic enzymes, cell-surface receptors), which can be involved as causal agents in diseases. The knowledge of microbial genomics, transcriptional factors, dynamics in proteomes (different isoforms and post-translational modifications) and, in general, dynamics in biological systems, can lead to biomarker identification and therapeutic targets, while advances in sampling techniques and structure-determination strategies, as well as target-identification methods, represent key steps in marine and earth drug discovery (Fig. 1) [4, 9].




Fig. (1). In nature, hidden and unexplored marine and earth surfaces are a vast resource of natural products with antimicrobial properties. Omics technologies as powerful high throughput tools to approach drug discovery and development.

MECHANISM OF ACTION OF THE ANTI-INFECTIVE DRUGS

Juan Manuel Favela- Hernández, PhD. Faculty of Chemistry, UJED, Gómez Palacio, Dgo., and Mexican Institute of Multidisciplinary Sciences, AVICENA, Torreón, Coahuila, Mexico

Possible Cutaneous Adverse Effects of Anti-Infective Vaccinations

Sevgi Akarsu^{1,*} and Fatma Polat²

¹ Dokuz Eylul University, Faculty of Medicine, Department of Dermatology, 35340 Inciralti, Izmir, Turkey

² Dermatologist; Kızılırmak District, Dumlupınar Boulevard, Next Level Residence, No: 3A/13, 06530, Çankaya, Ankara, Turkey

Abstract: Although commonly used anti-infective vaccines in clinical practice are generally safe, certain local or systemic adverse reactions related to them may rarely occur. Actually, considering the general vaccination rates, the incidence of serious skin reactions (*e.g.* . angioedema, anaphylaxis, Stevens–Johnson syndrome) is very low but vaccine-associated local cutaneous reactions such as erythema, edema, tenderness and pain at the injection sites are one of the most common complications of vaccines. Furthermore, a wide variety of specific or non-specific localized or generalized cutaneous adverse effects (*e.g.* lichenoid eruption, granuloma annulare, pseudolymphoma, erythema nodosum, erythema multiforme, Gianotti-Crosti syndrome, urticaria, lupus erythematosus, bullous pemphigoid, purpura) have been reported in the literature related with commonly used anti-infective vaccines. In this chapter, these adverse cutaneous reactions potentially associated with anti-infective vaccines were summarized with a comprehensive literature review.

Keywords: Adverse reaction, Anti-infective vaccination, Bacillus calmette-guérin vaccine, Complication, Cutaneous, Diphtheria and pertussis vaccine, Human papilloma virus vaccine, Hepatitis B virus vaccine, Influenza vaccine, Measles, Meningococcal vaccine, Mumps and rubella vaccine, Pneumococcal vaccine, Rash, Skin, Side effect, Tetanus, Vaccine, Varicella vaccine, COVID-19 vaccine.

INTRODUCTION

Vaccination remains the most important and successful public health intervention, as it prevents morbidity and mortality from common infectious diseases. With the increasing number of available and recommended vaccines worldwide, there are

* Corresponding author Sevgi Akarsu: Dokuz Eylul University, Faculty of Medicine, Department of Dermatology, 35340 Inciralti, Izmir, Turkey; Tel: +90 232 4123860, GSM: 05301194682, Fax: +90 232 4454252; E-mail: sevgi.akarsu@deu.edu.tr

raising concerns about the potential adverse effects associated with vaccines [1] Vaccines used for achieving immunization against infectious diseases are solutions containing live attenuated pathogens (usually viruses), inactivated whole pathogens, toxoids (an inactivated form of the toxin produced by bacteria that causes the disease), or parts of the pathogens (*e.g.* natural or recombinant proteins, polysaccharides, conjugated polysaccharide or virus-like particles) (Table 1, modified from Vetter *et al.* 2018) [1 - 3]. They are administered orally, subcutaneously, or intramuscularly. Vaccines are composed of preservatives, adjuvants, antibiotics, stabilizer, and manufacturing by-products in addition to immunogens (bacterial or viral antigens). In various vaccines, egg proteins, gelatin, aluminum hydroxide, aluminum potassium, or aluminum phosphate, thimerosal, 2-phenoxyethanol, formaldehyde, neomycin and/or polyethylene glycol are found separately or often together (Table 2) as vaccine constituents [1, 4, 5].

Table 1. Different Types of Vaccines.

Vaccine Types	Examples
Live attenuated vaccines	Measles, mumps, rubella, varicella (<i>Priorix Tetra, ProQuad</i>), rotavirus (<i>Rotarix, Rotavac</i>), herpes zoster (<i>Zostavax</i>), influenza (<i>Flumist</i>), oral poliovirus (<i>OPV</i>), yellow fever (<i>Stamaril</i>), <i>etc.</i>
Inactivated vaccines	Whole-cell pertussis (<i>Tritanrix</i>), hepatitis A (<i>Havrix, Vaqta</i>), rabies (<i>Rabipur</i>), tickborne encephalitis (<i>Encepur</i>), Japanese encephalitis (<i>Ixiaro</i>), cholera (<i>Dukoral</i>), COVID-19 vaccine (<i>Sinovac, Sinopharm, Covaxin</i>), <i>etc.</i>
Split and subunit protein vaccines (natural or recombinant)	Influenza (<i>Fluarix, Fluarix Tetra, Flulaval, Intanza, Vaxigrip, etc.</i>), acellular pertussis, hepatitis B (<i>Engerix B, Recombivax HB</i>), human papillomavirus (<i>Cervarix, Gardasil, Gardasil 9</i>), meningococcal B (<i>Bexsero, Trumenba</i>), malaria (<i>Mosquirix</i>), herpes zoster (<i>Shingrix</i>), COVID-19 vaccine (<i>Novavax, Soberana</i>), <i>etc.</i>
Toxoid vaccines	Tetanus, diphtheria, acellular pertussis (as part of DTaP combination vaccines: <i>Boostrix, Infanrix, Adacel, etc.</i>)
Polysaccharide vaccines	Pneumococcal polysaccharide vaccine (<i>Pneumovax 23</i>), meningococcal polysaccharide vaccine (<i>Mencevax</i>), <i>etc.</i>
Polysaccharide conjugate vaccines	Meningococcal C (<i>Neisvac</i>), A (<i>MenAfriVac</i>), ACWY (<i>Nimenrix, Menveo, Menactra</i>), pneumococcal conjugate vaccine (<i>Prevnar, Prevnar 13, Synflorix</i>), Haemophilus influenzae type b (<i>ACT-HIB</i>)
Reassortant live attenuated	Rotavirus (<i>RotaTeq</i>)
Viral vector DNA vaccines	COVID-19 vaccine (<i>Sputnik V, Oxford-AstraZeneca, Johnson & Johnson</i>)
mRNA vaccines	COVID-19 vaccine [<i>Pfizer (BNT162b2, USA), Moderna (mRNA-1273)</i>]

Table 2. Vaccine Constituents in Various Vaccines.

Vaccine Constituents	Vaccines
Egg proteins	MMR, influenza, yellow fever, tick-borne encephalitis, rabies vaccines, <i>etc.</i>
Gelatin	MMR, Japanese encephalitis virus, varicella, DTaP, <i>etc.</i>
Aluminum hydroxide, aluminum potassium, or aluminum phosphate	DTaP, DTaP/poliomyelitis/Haemophilus influenzae, quadrivalent HPV vaccine, hepatitis A, hepatitis B vaccines, <i>etc.</i>
Thimerosal	Influenza, DTaP, pneumococcus, meningococcus, hepatitis B, <i>etc.</i>
2-phenoxyethanol	DTaP, hepatitis A inactivated and hepatitis B recombinant vaccine, <i>etc.</i>
Formaldehyde	Influenza, poliomyelitis, DTaP, hepatitis B vaccine, <i>etc.</i>
Neomycin	MMR, DTaP, hepatitis, varicella, influenza, rabies vaccines, <i>etc.</i>
Polyethylene glycol	Influenza, hepatitis B, pneumococcal conjugate vaccine, mRNA COVID-19 vaccine, <i>etc.</i>

Different vaccines targeting the same pathogen can rely on very different concepts, each having advantages and limitations. Life-long immunity is possible after 1 or 2 doses with live attenuated vaccines that elicit both antibodies and cell-mediated immunity, but they are contraindicated in immunocompromised individuals and pregnant women. While disseminated or prolonged vaccine-strain infections after receiving a live vaccine such as varicella, measles–mumps–rubella (MMR), oral polio or Bacille Calmette–Guérin (BCG) vaccine are exceedingly rare, they are more common complications in immunocompromised populations. The presence of severe T-cell immunodeficiency or a household member with a similar immunodeficiency is therefore an absolute contraindication for immunization with any form of live vaccine. On the other hand, non-live vaccines which contain inactivated whole pathogens or only parts of them such as proteins or polysaccharides (subunit vaccines) generally have a good safety profile even in immunocompromised individuals. However, a major limitation of these vaccines is that their duration of protection tends to be shorter than with live vaccines, and requiring multiple primary and booster doses to achieve long-term immunity. In addition, they have limited immunogenicity and therefore adjuvants are frequently required to improve it [2, 3].

Vaccination against viral and bacterial agents widely performed worldwide is generally safe. Vaccine-associated local or systemic complications may rarely occur ranging from 4.8 to 83 per 100,000 doses of the most frequently used vaccines [1]. Among them cutaneous adverse effects ranging from local (transient pain, tenderness, burning sensations, erythema, swelling, induration, locoregional adenopathy) to generalized skin reactions are very rare compared to the

SUBJECT INDEX

A

- Acid 17, 30
 clavulanic 30
 folinic 17
Acinetobacter baumannii 89, 94
Actinomyces 82
 Action 52, 79
 antimicrobial 79
 chloroquine-potentiating 52
 Activity 33, 34, 35, 47, 48, 49, 51, 53, 54, 55,
 56, 57, 60, 61, 62, 78, 79, 80, 81, 84, 89
 anti-leukemic 55
 anti-microbial 89
 bioactive 80
 chloroquine enhancement 56
 enhancement indices (AEI) 51
 enzymatic 84
 inhibitory 56
 of DNA topoisomerases 78, 79
 transcription factor 81
 Acute 1, 11, 12, 14, 15, 93
 gastroenteritis 93
 macular neuroretinopathy 15
 retinal necrosis (ARN) 1, 11, 12, 14
 Acyclovir, oral 11, 12
 Adjuvant therapy 14
 Adverse effects, vaccine-related 135
 Adverse reactions 116, 119, 133, 138
 cutaneous 119, 133, 138
 systemic 116
 Agents 1, 24, 33, 34, 44, 64, 74, 80, 86, 95,
 118, 126
 antimicrobial 74
 antineoplastic 80
 bacterial 118
 chemosensitising 33
 industrial 95
 infectious 1
 reversing 34
 tuberculostatic 126
 Aminoglycoside phosphotransferase 94
 Analysis 87, 90, 91, 98
 metabolic 98
 metabolomic 87, 98
 transcriptomic 87, 90, 91
 Angiolymphoid hyperplasia 124
 Anti-infective 1, 74, 76, 88, 89
 agents 1, 74, 76, 88, 89
 drugs 76, 89
 Antibiotics, oral 5
 Antifungals drugs 4, 7, 9
 systemic 9
 Antimalarial activity 48, 49, 50, 51, 53, 54,
 59, 60
 Antimalarial drugs 26, 48, 58, 59
 chloroquine-based 48
 Antimicrobial 16, 77, 78, 79, 81, 82, 88, 90,
 91, 96, 98
 activity 77, 78, 79, 81, 82, 96, 98
 drugs 16, 88, 90, 91
 Antioxidant 77
 Antiplasmodial activity 32, 36, 37, 43, 52, 54,
 57, 58
 inherent 52
 intrinsic 32, 43, 52, 57, 58
 synergise 37
 Antiviral treatment 11
 Aplastic anemia 128
 Aspergillus in endogenous endophthalmitis 8
 ATP-binding cassette (ABC) 28, 42, 78, 79
 ATPase activity 78, 79
 Autoimmunity 133

B

- Bacillus calmette-guérin vaccine 124
 Bacteria 3, 6, 74, 78, 79, 80, 81, 89, 92, 93,
 98, 117
 drug-resistant 80
 resistant 74
 Bacterial infections 6, 7, 30
 Basal cell carcinoma 125
 BCG 124, 125, 126

M. Iqbal Choudhary (Ed.)

All rights reserved-© 2024 Bentham Science Publishers

Subject Index

vaccination 125, 126
vaccine 124, 125, 126
Biogenic silver nanoparticle 79
Bioinformatic 81, 90, 97
analysis 81
tools 90, 97
Biosynthesis pathway 100
Biosynthetic 75, 81, 82, 85, 96, 97
gene clusters (BGC) 75, 81, 82, 85, 96, 97
pathways 97
Bovis-associated systemic infection 126

C

Cancer, multidrug-resistant 63
Carcinomas 131
oral cavity 131
Cellular DNA polymerase 12
Cellulitis 131
Chemosensitisers 33, 38, 45, 63
natural 63
Chickungunya 10
Chloroquine-resistance reversal 32, 33, 37, 39,
40, 42, 43, 44, 45, 46, 47, 48, 49, 51, 53,
54, 55, 56, 58, 63, 64
activities 47, 55
agents 37, 39, 40, 42, 43, 44, 45, 46, 47, 48,
49, 51, 53, 54, 55
applications 32
compounds 63, 64
effect 56, 58
Chloroquine reversal agents 63
Chorioretinitis 14
Chromatographic columns 87
Chronic HBV infection 121
Column chromatography 51
Combination therapy 9, 16, 30
Conditions 17, 75, 86, 87, 89, 90, 121, 127,
131, 135, 136
inflammatory dermatologic 121
life-threatening 136
Congenital 14, 15, 122
infection 14, 15
rubella syndrome 122
Conjunctiva 2
Conjunctivitis 14
Contact dermatitis 133
Coumermycin 78
COVID-19 116, 117, 120, 132, 133, 134, 135
vaccination 134

Frontiers in Anti-Infective Drug Discovery, Vol. 10 151

vaccines 116, 117, 120, 132, 133, 135
Cutaneous reactions 116, 119, 125, 126, 131,
133, 134, 137, 138
adverse 116, 119
vaccine-associated local 116

D

Dengue 15
chorioretinitis 15
fever 15
retinitis 15
retinochoroiditis 15
Dermatitis 120, 122, 125, 130
exfoliative 125
granulomatous 130
Dermatolipomyonecrosis 128
Dermatomyositis 132
Diabetes mellitus 7
Disease 4, 13, 14, 15, 17, 25, 48, 54, 76, 92,
95, 96, 117, 126, 128, 130, 136
allergic 126
chronic 76, 92, 130
chronic progressive neurodegenerative 14
concurrent systemic 4
inflammatory 54
mediated severe 136
meningococcal 128
prognosis 96
viral 15
DNA 12, 77, 78, 79, 80, 81, 82, 85, 86, 87
binding process 81
duplexes, successful 86
microarrays 86, 87
polymerase, inhibiting 12
topoisomerases 78, 79
Drug(s) 2, 4, 5, 6, 8, 11, 13, 14, 26, 27, 29, 33,
60, 63, 80, 83, 89, 90, 91, 120
anitmicrobial 91
anti-allergy 120
anti-microbial 2
antiviral 11
gene-encoding 83
herbal antimalarial 60
hypersensitivity syndrome 120
immunomodulatory 14
immunosuppressive 13
oral 4
Drug discovery 24, 29, 31, 32, 74, 75, 81, 82,
88, 95, 96, 97, 99

- antimalarial 31
- of anti-infective agents 88
- pipelines 95
- process 29
- Drug resistance 88, 90, 91, 94
 - bacterial 94
 - combat 90
 - microbial 88
- Drug-resistance reversal 31, 32, 37
 - antimalarial 32

E

- Eczema 130
- Edema 116, 121, 122, 123, 127, 128, 131, 132
 - acute hemorrhagic 122
 - ranging 127
- Effect 12, 14, 50, 51, 57, 60, 78, 79, 80, 81
 - amodiaquinepotentiation 60
 - antagonistic 50, 57
 - antibacterial 78
 - antimicrobial 79
 - antiviral 12, 14
 - cytotoxic 51, 81
 - cytotoxin 80
- Efficacy 5, 6, 10, 15, 25, 31, 36, 47, 60, 64, 126
 - antimalarial 60
 - oral 36
- Efflux 29, 39, 88
 - pump inhibitors 29
 - pumps 88
 - transporter 39
- Efforts, accelerating 64
- Endogenous endophthalmitis 2, 4, 7, 8, 10
- Endophthalmitis 1, 2, 3, 4, 5, 6, 7, 9, 14
 - aspergillus 9
 - treatment 6
- Environment 4, 81, 83, 84, 86, 89
 - anti-bacterial 4
 - cellular 86
 - tumor 81
- Enzymatic transformations 46
- Enzymes 30, 76, 83, 88, 95, 96, 99
 - drug-metabolizing 88
 - metabolic 76
- Epstein Barr virus (EBV) 10, 11

F

- Factors 49, 54, 57, 60, 61, 75, 76, 85, 86, 89, 90, 130
 - biofilm-formation 89
 - nutritional 76
 - synergistic 61
 - transcription 75, 76
 - transcriptional 76
- Fever, yellow 117, 118
- Flow cytometry sorting 84
- Foscarnet treatment 12
- Fungal infection 4, 6, 7

G

- Gene clusters 75, 81, 82, 83, 85, 96, 97, 100
 - biosynthetic 75, 81, 82, 85, 96, 97
 - harbor biosynthetic 85
- Gene expression 75, 85, 86, 90
 - microarray technologies 75
- Genes 27, 28, 82, 83, 84, 85, 86, 87, 94, 96, 100
 - biosynthetic 85
 - biosynthetic cluster 84
 - housekeeping 94
 - resistant 96
- Genetic manipulation 82, 83
- Genome mining 82
- Genomics 76, 81
 - microbial 76
 - and metagenomics 81
- Gianotti-Crosti syndrome 116, 122, 124
- Glycoprotein 121
- Green fluorescent protein (GFP) 84
- Growth 3, 25, 50, 89, 129
 - economic 25
 - planktonic 89

H

- Haem 37
 - oxygenase 37
 - polymerase 37
- Haemophilus influenzae* 2
- HBV 121, 122
 - nonglycosylated 121
 - vaccination 121
 - vaccine 121, 122
- Head, polymeric hydrophilic 46

Subject Index

Hemagglutinin 123, 131
 pertussis 123
Hepatitis 116, 117, 118, 119, 121
 B virus (HBV) 116, 119, 121
Herbal concoctions 60, 62
Herpes simplex virus (HSV) 10, 11, 12
Herpetic retinitis 11, 12
High-resolution mass spectrometry (HRMS)
 99
HPV vaccination 131, 132
Human papillomavirus vaccine 131
Huntington's disease 76
Hydrolysis 79
Hypersensitivity 11, 119, 120, 127, 130, 134,
 136, 137
 fatal 136
 severe delayed cutaneous 119
 reaction 11, 120
 vasculitis 127, 130
Hypotrichosis 122

I

Immune response 1, 14
Immunity, cell-mediated 118
Infectious diseases 83, 96, 97, 117, 132
 intractable 83
Infective endocarditis 7
Inflamed eyes 5
Inflammation 1, 5, 6, 10, 11, 13, 15, 17, 76
 acute 15
 chronic non-granulomatous 11
 ocular 10, 13
Inflammatory response 14
Influenza vaccine 116, 120, 124, 130, 136,
 137
Injection 6, 8, 10
 intravitreal antibiotic 10
 intravitreal antifungal 8
 steroid 6
Injection technique 119
Intraocular 2, 9
 infection 2
 penetration 9
Intravenous immunoglobulins 15
Intravitreal 4, 5, 6, 10, 17
 antibiotics 4, 5, 10
 clindamycin 17
 steroids 6
Isobologram method 49, 56, 58

Frontiers in Anti-Infective Drug Discovery, Vol. 10 153

J

Japanese encephalitis virus 118
Johnson syndrome 116, 119, 130

K

Kawasaki disease 125, 127
Keratinocytes 121, 135
Keratoacanthoma 127
Keratouveitis 11

L

Lesions, retinochoroiditis 15
Liquid 75, 99
 chromatography 99
 gas chromatography (LGC) 75
Lupus erythematosus 116, 121, 122, 131, 132
 cutaneous 122, 131
 systemic 132

M

Maculopapular eruption 137
Magnetic nuclear resonance (MNR) 96, 98, 99
Malaria 57, 59, 60
 therapy 59
 treatment 57, 60
Mangifera indica 60
Mass 92, 93, 95, 96, 99
 spectrometers 99
 spectrometry (MS) 92, 93, 95, 96, 99
Measles infection 14
Mechanisms 9, 11, 29, 37, 42, 53, 77, 78, 79,
 82, 88, 94, 96, 100, 134, 136
 complimentary 9
 drug-resistance 42
 haematin-binding 53
 immune-mediated hypersensitivity 134
 microbial-resistance 82
Meningitis 94, 125, 127
 tuberculosis-related 125
MMR 122, 123
 vaccination 123
 vaccine 122, 123
Monotherapy 9, 16
Mycobacterium tuberculosis 90, 124

N

Natural 46, 48, 74, 76, 79, 80, 81, 82, 90, 95, 96, 97, 99, 125
 mycobacterial infection 125
 products (NP) 46, 48, 74, 76, 79, 80, 81, 82, 90, 95, 96, 97, 99
Neisseria meningitidis 127, 128
Neutrophilic dermatosis 131
Next-generation sequencing (NGS) 75, 85, 86, 97
Nicolau syndrome 120
NMR 98
 spectrometers 98
 spectroscopy functions 98
 techniques 98
Non-necrotizing herpetic retinopathy (NNHR) 13
Non-ribosomal peptide synthases (NRPS) 96
Nuclear magnetic resonance (NMR) 75, 92, 95, 98, 99

P

Parasitic Infections 15
Penicillin-binding protein (PBP) 95
Polymerase chain reaction (PCR) 11, 82, 85
Polysaccharide conjugate vaccines 117
Post-translational modifications (PTM) 76, 84, 94, 100
Products 75, 81
 antimicrobial 81
 natural drug-encoded 75
Progressive outer retinal necrosis (PORN) 11, 12
Protein(s) 29, 76, 85, 92, 94, 132
 biosynthesis 94
 damage pathways 29
 lipid-nanoparticle-encapsulated RNA encoding SARS-CoV-2 spike 132
 properties 92
 ribosome 85
 signaling 76
Proteomic and metabolomics technologies 76

Q

Quinoline drug-resistance reversal agents 47

R

Reactions 85, 120, 121, 125, 127, 135, 138
 immune-mediated 120, 121, 138
 immunologic 135
 necrotizing granulomatous 127
 polymerase chain 85
 severe delayed hypersensitivity 125
Reactive oxygen species (ROS) 79, 80
Resistance 5, 6, 12, 26, 27, 28, 29, 43, 48, 50, 63, 64, 93, 95, 100
 aminoglycoside 95
 antibiotic 100
 antimicrobial 63
 bacterial 93
 falciparum multidrug 26
 phenotypical multidrug 100
 streptomycin 93
Retinal necrosis 13
Retinopathy 14
Reversal 25, 48
 agents, antimalaria drug-resistance 25
 multidrug-resistance 48

S

Sjögren's syndrome 132
Skin reactions 116, 120
Solid-phase-extraction (SPE) 98
Staphylococcus aureus 2, 77, 78, 79, 94
Synthesis 11, 36, 39, 43, 44, 94
 block DNA 11

T

Therapies, active antiretroviral 13

U

Ulcer, necrotic 125
Ulceration, oral 135

V

Vaccine(s) 128, 136, 137
 coronavirus 137
 hypersensitivity 136
 meningococcus 128
Varicella zoster virus (VZV) 10, 11, 12, 129

Subject Index

Frontiers in Anti-Infective Drug Discovery, Vol. 10 155

Viral vector DNA vaccines 117, 132

W

Wound infections 5, 94



PROF. DR. M. IQBAL CHOUDHARY

Dr. M. Iqbal Choudhary is a Distinguished National Professor of Organic/Bioorganic Chemistry and Director at the International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research), and Coordinator General of COMSTECH (OIC Ministerial Committee). He is among the most prominent scientists of Pakistan, recognized for his original contributions in the fields of natural products and bioorganic chemistry. He has written and edited 27 books, most of which have been published in USA and Europe. He is also the author of over 1000 research papers and chapters in top international science journals of the West as well as 27 US patents (H-index: 73 & Citations: 31,000). He is the Volume Editor of many international book series and journals. He has served as a visiting faculty in many prestigious universities of the world including Cornell University (New York), Purdue University (Indiana), Pennsylvania State University (Pennsylvania), Scripps Institution of Oceanography (San Diego, California), The University of Rhode Island (Rhode Island), and other top Universities.